A Double Blind Randomized Controlled Evaluation of the HBLPADD-coil Transcranial Magnetic Stimulation (TMS) Device - Efficacy and Safety In Subjects With ADHD.

NCT ID: NCT01723319

Last Updated: 2012-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives:The purpose of the study is to explore the efficacy and safety of HBLPADD Coil deep brain TMS in subjects with ADHD.

Patient Population: The intention is to treat 40 patients diagnosed with ADHD. The patients will be of all racial, ethnic and gender categories, ranging from 18 to 65 years of age.

Structure: The study is a randomized, prospective, 5 weeks, double blind study. Blinding: The treatment administrator and the study personnel and patients will be masked to the treatment being administrated.

The study group will receive active dTMS treatment and the control group will receive an inactive, sham treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADHD

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ADHD TMS brain stimulation clinical improvement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

deep TMS treatment

Group Type EXPERIMENTAL

HBLPADD coil deep TMS

Intervention Type DEVICE

20 daily deep TMS treatment

2

inactive treatment

Group Type SHAM_COMPARATOR

Sham

Intervention Type DEVICE

inactive treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HBLPADD coil deep TMS

20 daily deep TMS treatment

Intervention Type DEVICE

Sham

inactive treatment

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients between the ages of 18-65(male and female).
2. Diagnosed as suffering from Attention-Deficit Hyperactivity Disorder according to the DSM IV.
3. Patients taking medication for ADHD will give their consent to stop those medication 48 before entering the study and throughout the daily treatments.
4. Gave informed consent for participation in the study.
5. If referred by the treating psychiatrist, he or she approves of the subjects participation in the study.

Exclusion Criteria

1. Suffering from other diagnosis on axis 1.
2. antipsychotic treatment with stabilizers; medications from the Benzodiazepines group are allowed, if need be,to a maximum dosage of 2 mg lorazepam.
3. History of lack of tolerance to TMS.
4. Axis 2 diagnosis according to the DSM IV.
5. Substantial suicidal risk as judged by the treating psychiatrist or by an independent psychiatrist.
6. Attempted suicide in the past year.
7. High and not controlled blood pressure.
8. History of epilepsy, seizure, or hot spasm.
9. History of epilepsy or seizure in first degree relatives.
10. History of a significant head injury
11. History of metal in the head (outside the mouth space).
12. Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.
13. Use of hearing aids for hearing loss.
14. History of frequent or severe headaches.
15. History of drug or alcohol abuse during the last year.
16. Inability to achieve satisfying level of communication with the subject.
17. Participation in current clinical study or clinical study within 30 days prior to this study
18. Patients declared as legally incompetent, with an appointed physical guardian and/or cannot sign informed consent due to cognitive incompetence.
19. Women - Pregnancy or not using a reliable method of birth control.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shalvata Mental Health Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

yechiel levkovitz, MD

Role: PRINCIPAL_INVESTIGATOR

Shalvata Mental Health Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shalvata

Hod HaSharon, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yechiel Levkovitz, MD

Role: CONTACT

Phone: 972-9-7478644

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yechiel levkovitz, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SH-0025-12

Identifier Type: -

Identifier Source: org_study_id